Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

sruilk/iStock via Getty Images Investment Overview Arcutis (NASDAQ:ARQT) IPO'd back in January 2020, raising ~$160m via the issuance of 9.375m shares priced at $17 per share. At the time, the company described itself as follows:    a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis is currently developing three novel compounds (ARQ-151, ARQ-154 and ARQ-252) f ...